Interventional oncology firm Delcath's Q2 revenue beats estimates

Delcath Systems

06/08/2025 13:11

Overview

Delcath Q2 2025 revenue grows significantly, beating analyst expectations, per LSEG data

Net income turns positive at $2.7 mln, compared to loss last year

Co activates three new U.S. centers, expanding treatment network

Outlook

Delcath projects 2025 revenue of $93 mln to $96 mln

Company expects 2025 gross margins between 83% and 85%

Delcath anticipates positive adjusted EBITDA each quarter in 2025

Result Drivers

HEPZATO SALES - Significant revenue growth driven by HEPZATO KIT sales, reaching $22.5 mln, up from $6.6 mln in Q2 2024

NEW CENTERS - Activation of three new U.S. centers, increasing total to 20 active centers, supporting revenue growth

R&D EXPANSION - Increased R&D expenses due to clinical team expansion and new trial initiations for metastatic colorectal and breast cancer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$24.16 mln
$22.80 mln (6 Analysts)
Q2 EPS
$0.07
Q2 Net Income
$2.70 mln
Q2 Gross Profit
$20.84 mln
Q2 Operating Expenses
$18.25 mln
Q2 Operating Income
$2.59 mln


Press Release: ID:nBwc2VhvRa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)